| Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells A Derer, M Spiljar, M Bäumler, M Hecht, R Fietkau, B Frey, US Gaipl Frontiers in immunology 7, 610, 2016 | 135 | 2016 |
| Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients M Hecht, L Zimmer, C Loquai, C Weishaupt, R Gutzmer, B Schuster, ... Annals of Oncology 26 (6), 1238-1244, 2015 | 134 | 2015 |
| PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis M Hecht, M Büttner-Herold, K Erlenbach-Wünsch, M Haderlein, R Croner, ... European journal of cancer 65, 52-60, 2016 | 130 | 2016 |
| Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies M Rückert, L Deloch, R Fietkau, B Frey, M Hecht, US Gaipl Strahlentherapie und Onkologie 194 (6), 509-519, 2018 | 109 | 2018 |
| Radiotherapy and the immune system: More than just immune suppression M Rückert, AS Flohr, M Hecht, US Gaipl Stem Cells 39 (9), 1155-1165, 2021 | 77 | 2021 |
| CD8+ and regulatory T cells differentiate tumor immune phenotypes and predict survival in locally advanced head and neck cancer A Echarti, M Hecht, M Büttner-Herold, M Haderlein, A Hartmann, ... Cancers 11 (9), 1398, 2019 | 77 | 2019 |
| Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 M Hecht, AO Gostian, M Eckstein, S Rutzner, J von der Grün, T Illmer, ... Journal for immunotherapy of cancer 8 (2), 2020 | 61 | 2020 |
| Efavirenz has the highest anti-proliferative effect of non-nucleoside reverse transcriptase inhibitors against pancreatic cancer cells M Hecht, S Erber, T Harrer, H Klinker, T Roth, H Parsch, N Fiebig, ... PLoS One 10 (6), e0130277, 2015 | 58 | 2015 |
| Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells R Sun, N Sundahl, M Hecht, F Putz, A Lancia, A Rouyar, M Milic, A Carré, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 56 | 2020 |
| Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system M Hecht, T Harrer, M Büttner, M Schwegler, S Erber, R Fietkau, LV Distel Aids 27 (13), 2031-2040, 2013 | 55 | 2013 |
| Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of … R Fietkau, M Ghadimi, R Grützmann, UA Wittel, L Jacobasch, W Uhl, ... Journal of Clinical Oncology 40 (16_suppl), 4008-4008, 2022 | 53 | 2022 |
| Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy R Merten, M Hecht, M Haderlein, L Distel, R Fietkau, L Heinzerling, ... Strahlentherapie und Onkologie 190 (12), 1169, 2014 | 47 | 2014 |
| Immune biological rationales for the design of combined radio-and immunotherapies M Hader, B Frey, R Fietkau, M Hecht, US Gaipl Cancer Immunology, Immunotherapy 69 (2), 293-306, 2020 | 44 | 2020 |
| Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint … JG Zhou, AJ Donaubauer, B Frey, I Becker, S Rutzner, M Eckstein, R Sun, ... Journal for Immunotherapy of Cancer 9 (2), 2021 | 41 | 2021 |
| Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients M Hecht, F Meier, L Zimmer, B Polat, C Loquai, C Weishaupt, A Forschner, ... British journal of cancer 118 (6), 785-792, 2018 | 41 | 2018 |
| Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard … R Fietkau, M Hecht, B Hofner, D Lubgan, H Iro, O Gefeller, C Rödel, ... Radiotherapy and Oncology 144, 209-217, 2020 | 36 | 2020 |
| Spatial distribution of FoxP3+ and CD8+ tumour infiltrating T cells reflects their functional activity R Posselt, K Erlenbach-Wünsch, M Haas, J JeΔberger, M Büttner-Herold, ... Oncotarget 7 (37), 60383, 2016 | 35 | 2016 |
| Targeted therapy, chemotherapy, immunotherapy and novel treatment options for different subtypes of salivary gland cancer SK Mueller, M Haderlein, S Lettmaier, A Agaimy, F Haller, M Hecht, ... Journal of Clinical Medicine 11 (3), 720, 2022 | 33 | 2022 |
| Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma M Haderlein, C Scherl, S Semrau, S Lettmaier, M Hecht, R Erber, H Iro, ... Strahlentherapie und Onkologie 193 (11), 961, 2017 | 33 | 2017 |
| Palbociclib induces senescence in melanoma and breast cancer cells and leads to additive growth arrest in combination with irradiation T Jost, L Heinzerling, R Fietkau, M Hecht, LV Distel Frontiers in Oncology 11, 740002, 2021 | 32 | 2021 |
